Skip to main
QNCX
QNCX logo

QNCX Stock Forecast & Price Target

QNCX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Quince Therapeutics Inc's strong safety record from prior clinical trials and open-label extensions reinforces confidence in its favorable toxicity profile and long-term tolerability. High patient retention rates, indicated by participants' decisions to continue in open-label extensions, signal significant interest in the therapy, which may enhance future market potential. Additionally, the company’s ambitious pipeline expansion into conditions like Duchenne Muscular Dystrophy alongside its innovative drug delivery platform suggests robust scalability and growing opportunities within precision therapeutics for rare diseases.

Bears say

Quince Therapeutics Inc reported a net loss of $13.3 million for Q3 2025, indicative of the financial challenges often faced by early-stage biotechnology firms. The company's cash and short-term investments totaled $26.3 million as of September 30, 2025, which raises concerns about its liquidity and ability to fund ongoing research and development efforts given the significant loss. Additionally, with research and development expenses reaching $8.1 million, the financial metrics suggest that the company may struggle to maintain operational stability in the long term without external financing or a substantial increase in revenue.

QNCX has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quince Therapeutics Inc (QNCX) Forecast

Analysts have given QNCX a Buy based on their latest research and market trends.

According to 4 analysts, QNCX has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quince Therapeutics Inc (QNCX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.